Hansa Biopharma Interim Report January-September 2019
- Thursday, October 31, 2019, 2:38
- Business
- Add a comment
MALMÖ, Sweden, Oct. 31, 2019 /PRNewswire/ — – Positive results from a pooled analysis of Phase 2 trials with imlifidase for desensitization in highly sensitized kidney transplant patients were presented for the first time at the European Society of Organ Transplantation’s (ESOT) Congress…
About the Author
adminasapcorp has written 38957 stories on this site.